Inhibrx Inc
NASDAQ:INBX

Watchlist Manager
Inhibrx Inc Logo
Inhibrx Inc
NASDAQ:INBX
Watchlist
Price: 72.56 USD -1.92% Market Closed
Market Cap: $1.1B

Net Margin

-7 983.9%
Current
Declining
by 88 935.3%
vs 3-y average of 80 951.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-7 983.9%
=
Net Income
$-111.8m
/
Revenue
$1.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-7 983.9%
=
Net Income
$-111.8m
/
Revenue
$1.4m

Peer Comparison

Country Company Market Cap Net
Margin
US
Inhibrx Inc
NASDAQ:INBX
1.1B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.8B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.3B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 96% of companies in the United States of America
Percentile
4th
Based on 15 072 companies
4th percentile
-7 983.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Inhibrx Inc
Glance View

Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The company is headquartered in La Jolla, California and currently employs 106 full-time employees. The company went IPO on 2020-08-19. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological target. Its products pipeline includes: INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) protein that is comprised of two human AAT, molecules covalently linked to the fragment crystallizable (Fc) region of human immunoglobulin G4; INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate targeting death-receptor 5 (DR5) that designed with its sdAb platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis, and INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1.

INBX Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-7 983.9%
=
Net Income
$-111.8m
/
Revenue
$1.4m
What is Inhibrx Inc's current Net Margin?

The current Net Margin for Inhibrx Inc is -7 983.9%, which is below its 3-year median of 80 951.4%.

How has Net Margin changed over time?

Over the last 3 years, Inhibrx Inc’s Net Margin has decreased from -2 625.5% to -7 983.9%. During this period, it reached a low of -42 881.8% on Sep 30, 2023 and a high of 843 786% on Dec 31, 2024.

Back to Top